Chronic Myelomonocytic Leukemia Recruiting Phase 2 Trials for Ipilimumab (DB06186)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02397720Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaTreatment